Current Status of Senolytics and Senomorphics: Mechanistic Insights, Clinical Progress, and Future Directions

Background: Cellular senescence contributes to aging, chronic inflammation, and age-related diseases. Senolytics eliminate senescent cells, whereas senomorphics modulate their pathological activities, including the senescence-associated secretory phenotype (SASP). This review examines their mechanisms, preclinical and clinical evidence, safety, and translational challenges. Methods: Published mechanistic, preclinical, and clinical literature on senolytic and senomorphic therapies was reviewed, focusing on therapeutic targets, disease-specific findings, safety, and clinical translation. Results: Senolytics, including dasatinib plus quercetin, navitoclax, and fisetin, target senescent-cell survival pathways, whereas senomorphics, including rapamycin, metformin, and Janus kinase inhibitors, modulate inflammatory signaling and SASP-associated pathways. Preclinical studies suggest benefits across metabolic, cardiovascular, musculoskeletal, and neurodegenerative disease models. However, human evidence remains limited and heterogeneous. Early clinical studies demonstrate the feasibility of senescence targeting and changes in selected biomarkers, but consistent clinical benefit remains unestablished. Major challenges include senescent-cell heterogeneity, insufficiently validated biomarkers, treatment-related toxicity, and the physiological roles of senescence in tissue repair and tumor suppression. Conclusions: Senolytics and senomorphics are promising but investigational therapeutic strategies. Clinical translation requires validated biomarkers, disease-specific patient selection, improved therapeutic selectivity, adequately powered trials with clinically meaningful endpoints, and long-term safety assessment. Aligning therapeutic strategies with senescent-cell phenotypes, disease context, and treatment objectives may improve clinical relevance.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-13
DOI
https://doi.org/10.20944/preprints202611.1453.v1
Primary Topic
Telomeres, Telomerase, and Senescence
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Current Status of Senolytics and Senomorphics: Mechanistic Insights, Clinical Progress, and Future Directions

Pinki Mishra, Faraha Ahmed, Razia Khanam
3 links
Preprints.org
Telomeres, Telomerase, and Senescence
preprint

Current Status of Senolytics and Senomorphics: Mechanistic Insights, Clinical Progress, and Future Directions

Pinki Mishra, Faraha Ahmed, Razia Khanam
preprint en

Abstract

Background: Cellular senescence contributes to aging, chronic inflammation, and age-related diseases. Senolytics eliminate senescent cells, whereas senomorphics modulate their pathological activities, including the senescence-associated secretory phenotype (SASP). This review examines their mechanisms, preclinical and clinical evidence, safety, and translational challenges. Methods: Published mechanistic, preclinical, and clinical literature on senolytic and senomorphic therapies was reviewed, focusing on therapeutic targets, disease-specific findings, safety, and clinical translation. Results: Senolytics, including dasatinib plus quercetin, navitoclax, and fisetin, target senescent-cell survival pathways, whereas senomorphics, including rapamycin, metformin, and Janus kinase inhibitors, modulate inflammatory signaling and SASP-associated pathways. Preclinical studies suggest benefits across metabolic, cardiovascular, musculoskeletal, and neurodegenerative disease models. However, human evidence remains limited and heterogeneous. Early clinical studies demonstrate the feasibility of senescence targeting and changes in selected biomarkers, but consistent clinical benefit remains unestablished. Major challenges include senescent-cell heterogeneity, insufficiently validated biomarkers, treatment-related toxicity, and the physiological roles of senescence in tissue repair and tumor suppression. Conclusions: Senolytics and senomorphics are promising but investigational therapeutic strategies. Clinical translation requires validated biomarkers, disease-specific patient selection, improved therapeutic selectivity, adequately powered trials with clinically meaningful endpoints, and long-term safety assessment. Aligning therapeutic strategies with senescent-cell phenotypes, disease context, and treatment objectives may improve clinical relevance.

Preprints.org
Good health and well-being
Telomeres, Telomerase, and Senescence
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon